GZ-389988
GZ-389988 is an investigational pharmaceutical compound that has been studied for its potential therapeutic effects in the treatment of depression and anxiety disorders. It is classified as a selective serotonin reuptake inhibitor (SSRI) and is being developed by GlaxoSmithKline.
Mechanism of Action[edit | edit source]
GZ-389988 functions primarily as a selective serotonin reuptake inhibitor. SSRIs work by increasing the levels of serotonin in the brain, a neurotransmitter associated with mood regulation. By inhibiting the reuptake of serotonin into the presynaptic neuron, GZ-389988 increases the availability of serotonin in the synaptic cleft, thereby enhancing serotonergic neurotransmission.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of GZ-389988 includes its absorption, distribution, metabolism, and excretion. While specific data on GZ-389988 is limited, SSRIs typically have a moderate to high oral bioavailability, are extensively metabolized in the liver, and have a half-life that allows for once-daily dosing.
Clinical Trials[edit | edit source]
GZ-389988 has undergone several phases of clinical trials to evaluate its efficacy and safety in treating major depressive disorder and generalized anxiety disorder. Preliminary results have shown promise, with patients experiencing significant improvements in mood and anxiety symptoms compared to placebo.
Side Effects[edit | edit source]
As with other SSRIs, GZ-389988 may cause side effects such as nausea, headache, dizziness, insomnia, and sexual dysfunction. It is important for patients to discuss potential side effects with their healthcare provider.
Regulatory Status[edit | edit source]
As of the latest update, GZ-389988 is still in the investigational stage and has not yet received approval from major regulatory bodies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Research and Development[edit | edit source]
Research on GZ-389988 is ongoing, with studies focusing on its long-term efficacy, safety profile, and potential use in other psychiatric disorders. The development of GZ-389988 is part of a broader effort to find more effective treatments for mental health conditions.
Also see[edit | edit source]
- Selective serotonin reuptake inhibitor
- Major depressive disorder
- Generalized anxiety disorder
- GlaxoSmithKline
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
